Refractory Status Epilepticus: Risk Factors and Analysis of Intubation in the Multicenter SENSE Registry
- PMID: 35948449
- DOI: 10.1212/WNL.0000000000201099
Refractory Status Epilepticus: Risk Factors and Analysis of Intubation in the Multicenter SENSE Registry
Abstract
Background and objectives: Refractory status epilepticus (RSE) bears significant morbidity and mortality. Therapy escalation and in some cases intubation are recommended. Most existing studies are retrospective and focus on intensive care units. We aimed to describe routine-care management and analyze determinants of RSE development and outcomes in a large multicenter cohort.
Methods: We performed post hoc analysis of an observational, cohort study, which prospectively registered all consecutive adults with SE at 9 centers from 3 central European countries. Only incident episodes were included. Ongoing SE despite 2 antiseizure medications was defined as RSE. Patients intubated during first-line or second-line treatments were excluded. Variables investigated included demographics, severity (Status Epilepticus Severity Score), etiology, and guideline-compliant treatment (defined as fixed minimum doses). Outcome parameters included survival and mRS at baseline, and discharge (good: 0-2, or absence of worsening compared with prehospitalization).
Results: Among 1,179 SE episodes from 1,049 adults, 996 patients were eligible (median age: 70 years, 52% female), of which 545 (54.7%) developed RSE. RSE was associated with higher baseline mRS (p < 0.001) and treatment deviation from guidelines (p < 0.001, OR 0.09; 95% CI 0.06-0.1). Good outcomes were observed in 52.7% of refractory patients, correlating with lower status epilepticus severity (p < 0.001), absence of acute etiology (p < 0.001, OR 0.5; 95% CI 0.3-0.7), adequate first-line benzodiazepine dose (p < 0.001, OR 2.5; 95% CI 1.6-4.0), shorter durations of SE and hospitalization (both p < 0.001), and lack of intubation (p < 0.001, OR 0.4; 95% CI 0.3-0.6). Most (71.7%) refractory patients were not intubated. Intubation was associated with younger age (p = 0.006), more severe consciousness disturbances (p < 0.001, OR 3.2; 95% CI 2.1-4.8), more severe SE types (p < 0.001), higher severity score (p = 0.009), acute etiologies (p = 0.01, OR 1.6; 95% CI 1.1-2.4), more antiseizure medications (p < 0.001), initial treatment after shorter latency (p = 0.01), worse outcomes (p < 0.001, OR 0.4; 95% CI 0.4-0.6), and longer hospitalizations (p < 0.001).
Discussion: Variables associated with RSE were identified, some potentially preventable. More than 70% of RSE were treated without intubation, suggesting that focal RSE without deep impairment of consciousness, in older patients, may be successfully treated outside ICUs.
Trial registration information: Original cohort study registered at the German Clinical Trials Register (DRKS00000725).
© 2022 American Academy of Neurology.
Similar articles
-
How much refractory is 'refractory status epilepticus'? A retrospective study of treatment strategies and clinical outcomes.J Neurol. 2023 Dec;270(12):6133-6140. doi: 10.1007/s00415-023-11929-2. Epub 2023 Aug 16. J Neurol. 2023. PMID: 37587268
-
Long-term outcome of refractory status epilepticus in adults: A retrospective population-based study.Epilepsy Res. 2017 Jul;133:13-21. doi: 10.1016/j.eplepsyres.2017.03.009. Epub 2017 Apr 2. Epilepsy Res. 2017. PMID: 28402834
-
Management of Refractory Status Epilepticus: An International Cohort Study (MORSE CODe) Analysis of Patients Managed in the ICU.Neurology. 2022 Sep 13;99(11):e1191-e1201. doi: 10.1212/WNL.0000000000200818. Epub 2022 Aug 2. Neurology. 2022. PMID: 35918156 Free PMC article.
-
Status epilepticus: Refractory and super-refractory.Neurol India. 2017;65(Supplement):S12-S17. doi: 10.4103/neuroindia.NI_958_16. Neurol India. 2017. PMID: 28281491 Review.
-
Treatment of Refractory Status Epilepticus With Continuous Intravenous Anesthetic Drugs: A Systematic Review.JAMA Neurol. 2024 May 1;81(5):534-548. doi: 10.1001/jamaneurol.2024.0108. JAMA Neurol. 2024. PMID: 38466294
Cited by
-
Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review.Neurol Res Pract. 2024 Apr 4;6(1):19. doi: 10.1186/s42466-024-00314-7. Neurol Res Pract. 2024. PMID: 38570823 Free PMC article.
-
Status epilepticus in the ICU.Intensive Care Med. 2024 Jan;50(1):1-16. doi: 10.1007/s00134-023-07263-w. Epub 2023 Dec 20. Intensive Care Med. 2024. PMID: 38117319 Review.
-
Efficacy and Tolerability of Intranasal Midazolam Administration for Antiseizure Treatment in Adults: A Systematic Review.Neurocrit Care. 2024 Oct;41(2):632-650. doi: 10.1007/s12028-024-01971-x. Epub 2024 Apr 5. Neurocrit Care. 2024. PMID: 38580802 Free PMC article.
-
Sustained effort network for treatment of status epilepticus/European academy of neurology registry on adult refractory status epilepticus (SENSE-II/AROUSE).BMC Neurol. 2024 Jan 4;24(1):19. doi: 10.1186/s12883-023-03505-y. BMC Neurol. 2024. PMID: 38178048 Free PMC article.
-
How much refractory is 'refractory status epilepticus'? A retrospective study of treatment strategies and clinical outcomes.J Neurol. 2023 Dec;270(12):6133-6140. doi: 10.1007/s00415-023-11929-2. Epub 2023 Aug 16. J Neurol. 2023. PMID: 37587268
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources